Patients
At 12/15/2022, a total of 90 patients were treated and included in this interim analysis (21 part 1; 20 part 2/RP2D (n=30)).

In part 1, 12 of 18 patients (66.7%) had stage IV disease, 26.7% had stage III disease, and 66.7% had received prior systemic therapy.

In part 2/RP2D, 18 of 30 patients (60%) had stage IV disease, 60% had received prior systemic therapy, and 26.7% were 60 years or older.

At RP2D, DOR was not reached, and the 6-month event-free rate was 59.4% (95% CI, 23.8%-82.8%)

Efficacy
The overall response rate (ORR) was 45.5% (95% CI, 32.8%-59.0%) at RP2D (see Table 2).}

CONCLUSIONS

Patients

Presented at EHA 2023 Hybrid Congress; June 8-15, 2023; Frankfurt, Germany. Data originally presented at the 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL, USA. Abstract P1366.